Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy

by Damiënne Marcus, Relinde I. Y. Lieverse, Carmen Klein, Amir Abdollahi, Philippe Lambin, Ludwig J. Dubois, Ala Yaromina
Published 2021-03-01

Human fibronectin extra domain B as a biomarker for targeted therapy in cancer

by Relinde I. Y. Lieverse, Damiënne Marcus, Alexander M. A. van derWiel, Evert J. Van Limbergen, Jan Theys, Ala Yaromina, Philippe Lambin, Ludwig J. Dubois
Published 2020-07-01

Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer

by Sebastian Sanduleanu, Alexander M.A. van der Wiel, Relinde I.Y. Lieverse, Damiënne Marcus, Abdalla Ibrahim, Sergey Primakov, Guangyao Wu, Jan Theys, Ala Yaromina, Ludwig J. Dubois, Philippe Lambin
Published 2020-05-01

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised contr...

by Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois, Philippe Lambin
Published 2020-06-01